Brind.

Amylyx Pharmaceuticals and Phoenix are continuing development of AMX0114 and conducting the PHOENIX Phase 3 trial for ALS.

1 report, 1 independent Updated Aug 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Amylyx Pharmaceuticals and Phoenix are continuing development of AMX0114 and conducting the PHOENIX Phase 3 trial for ALS.

Who's involved

What this event is mainly about
Amylyx PharmaceuticalsPhoenix

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • BenzingaAmylyx Halts Rare Brain Disorder Drug Program After Disappointing Trial Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) on Wednesday decided to discontinue the ORION program of AMX0035 (sodium phenylbutyr